Unverified80% confidenceFactExact time
Insilico Medicine于2023年将其AI设计的候选药物推进至临床II期试验，成为首个完全由AI设计并进入临床阶段的药物分子
1
Sources
80%
Confidence
Long-term
Relevance
5/17/2026
First Seen
Sources
Related Entities
Related Claims
Unverified2023年FDA发布了AI/ML药物开发讨论文件，但仅是初步探索74% similarUnverifiedAI在2023年辅助发现了新型抗生素71% similarUnverifiedIsomorphic Labs was founded in 2021 and is an independently operated AI pharmaceutical company under Alphabet.69% similarUnverifiedThe US FDA published the "Artificial Intelligence/Machine Learning-Based Software as a Medical Device Action Plan" in 2021, introducing the concept of a Predetermined Change Control Plan.64% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/10691API
curl https://kongchang.com/api/v1/knowledge/claims/10691MCP
get_claim(id=10691)